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Abstract 
 
Listeria monocytogenes is an intracellular bacterium and that causes serious diseases 
in animals and humans. Studies to understand the mechanisms disease are required, but first it 
is necessary to have a mouse model of oral infection and thus the aim of part of the project 
was the establishment of a mouse model of oral infection that uses the minimum bacterial 
concentration that achieves 100% of mortality. The results of the experiments showed that the 
minimum dose of 5x109 CFU/500µl was sufficient to kill all mice with a median survival of 
60 hours. 
Streptococcus pneumoniae is a human pathogen that causes a high mortality. S. 
pneumoniae has a wide range of virulence factors that include: surface proteins, enzymes, 
polysaccharide capsule and the toxin pneumolysin. One of the most important virulence 
factors is the pneumolysin, it is a member of the cholesterol-dependent cytolysins and has the 
ability to bind the membrane surface, oligomerize and consequently induces cell death. To 
produce a tool for study of the in vivo behaviour of S. pneumoniae and the role of the 
pneumolysin, the second part of the project made a recombinant penumolysin – negative S. 
pneumoniae that expressed green or red fluorescent protein.  
 
 
 
 
 
 
 
 
 
 
Keywords: Listeriosis, Listeria monocytogenes, mouse model of oral gavage, Streptococcus 
pneumoniae, pneumolysin
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Resumo 
 
Listeria monocytogenes é o agente etiológico da listeriose, uma doença que afeta 
predominantemente indivíduos imunocomprometidos, fetos, recém-nascidos e idosos. Pode 
igualmente afetar animais como ovelhas e cabras. A infeção está associada ao consumo de 
alimentos contaminados, alimentos pré-cozinhados, vegetais, carnes e produtos lácteos. A 
contaminação destes produtos pode ocorrer no ambiente de processamento. Esta bactéria 
consegue crescer a temperaturas muito baixas como 4ºC (psicrotrófica) e é capaz de tolerar 
temperaturas mais elevadas como 45ºC. Em relação ao valor de pH pode crescer entre os 
valores de 4.5 a 9.6. O largo espectro de temperaturas e valores de pH dificultam o controlo 
bacteriano nas indústrias visto que, é dentro destes valores que muitas das operações são 
efetuadas. 
A listeriose pode ocorrer em dois níveis distintos de doença, ao nível não invasivo que 
pode afetas adultos saudáveis onde os sintomas incluem vómitos e diarreia, enquanto o nível 
invasivo da doença, a sua forma mais agressiva pode manifestar-se sob a forma de meningite, 
septicemia e provocar o aborto em mulheres grávidas.  
L. monocytogenes é uma bactéria intracelular que possui vários fatores de virulência, 
entre eles duas internalinas – InlA e InlB -, que são utilizadas pela bactéria para que esta 
consiga atravessar a barreira intestinal, a barreira hematoencefálica e a barreira placentária. 
Com a ajuda destas internalinas a bactéria consegue entrar dentro da célula hospedeira onde 
posteriormente irá causar a morta da mesma. Para conhecer melhor os fatores que afetam este 
mecanismo e para entender melhor o papel e importância de certos genes associados à 
resistência desta bactéria a inúmeros fatores como, por exemplo, a sua resistência a metais, 
um modelo animal para estudos in vivo é necessário.  
Para a construção de um modelo animal eficaz foram, efetuadas mutações no fator de 
virulência InlA para que a bactéria se conseguisse ligar ao recetor das células epiteliais do 
ratinho, uma vez que existe uma forte especificidade em relação à espécies hospedeira, o que 
faz com que o tipo selvagem apenas se consiga ligar ao recetor das células epiteliais humana. 
Dado que a via natural de infeção ocorre através da ingestão de alimentos contaminados, a 
técnica de infeção preferencial para modelos in vivo que melhor se assemelha à infeção 
natural é a oral gavage. 
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O presente estudo teve como objetivo a elaboração de um modelo de base de infeção 
de ratinhos por oral gavage, onde se desejava alcançar 100% de mortalidade com a menor 
dose bacteriana possível. Os resultados mostraram que uma suspensão bacteriana com 
5x109CFU/500µl é suficiente para provocar 100% de mortalidade num período médio de 60 
horas.  
No presente estudo foi ainda possível a construção de mutantes da bactéria 
Streptococcus pneumoniae. A bactéria S. pneumoniae causa doenças invasivas, como a 
pneumonia, meningite e septicemia, e doenças não invasivas, como é o caso de otite média. 
Apesar de causar estes tipos de doenças, esta bactéria é um agente bacteriano comensal da 
nasofaringe não causando qualquer doença. Contudo de acordo com o estudo efetuado pela 
World Health Organization (WHO) em 2000, cerca de 826 000 crianças com menos de 5 anos 
de idade morreram de doença pneumocócica, sendo que 61% destas mortes ocorreram 
predominantemente em países Africanos e Asiáticos. 
As infeções pneumocócicas são transmitidas de pessoa para pessoa através de 
aerossóis. A primeira fase da infeção é a colonização da nasofaringe onde não há nenhum 
sintoma associado, podendo depois ocorrer dois cenários: a bactéria permanece sem causar 
qualquer doença ou alastra-se para outros órgãos, como os ouvidos ou os pulmões. Se a 
bactéria atingir os pulmões poderá causar pneumonia e, caso consiga atravessar a barreira 
mucosa, poderá ultrapassar a barreira hematoencefálica provocando a meningite. 
S. pneumoniae tem inúmeros fatores de virulência, entre os quais enzimas, proteínas 
de superfície, a cápsula polissacárida e a toxina pneumolisina (Ply). Um dos fatores mais 
importantes para a virulência da bactéria é a toxina pneumolisina que, apesar de ser dos 
fatores mais estudados o seu papel ainda não está totalmente classificado. O segundo objetivo 
deste estudo foi a criação de mutações em duas bactérias fluorescentes, S. pneumoniae D39 
GFP+ e S. pneumoniae D39 RFP+ (do inglês “Green flourescent protein” e “Red flourescent 
protein”), onde o gene da pneumolisina (ply) foi substituído pelo gene de resistência à 
espectinomicina. A inserção destas mutações não afetou a fluorescência da bactéria, e como 
tal, o trabalho futuro será a visualização in vivo do comportamento de S. pneumoniae na 
presença e na ausência da toxina pneumolisina o que irá permitir compreender melhor a 
influência quer da toxina pneumolisina quer dos outros fatores de virulência no potencial de 
virulência de S. pneumoniae D39. 
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1. Introduction  
 
1.1. Listeria monocytogenes 
Listeria monocytogenes, the causative organism of listeriosis1 a disease that affects 
humans mainly foetus, new-borns, and immunocompromised patients2 and animals, such as 
sheep’s and goats. Since the late 1980s L. monocytogenes is known as a food borne pathogen 
and its infection is related with the consumption of contaminated food or feed3, 4. 
L. monocytogenes is a Gram-positive bacterium, non-spore-forming rods with a length 
between 1 – 2 µm5, can grow over a wide spectrum of temperatures from 4ºC to 45ºC but the 
optimal growth temperature is 30ºC – 37oC. This bacterium, can survive in a range of pH 
values, namely from 4.5 to 9.64, this limits represent a problem to the food industry since 
many food products have this range of values6. It is known that L. monocytogenes is not a 
good forming biofilm bacterium, nevertheless it can still survive for several years outside the 
host if it is in a humid atmosphere7, and such ability contributes to difficult its control either 
in the food processing environment or the domestic.  
The genus Listeria is composed by fifteen species: L. monocytogenes, L. innocua, L. 
welshimeri, L. seeligeri, L. ivanovii, L. grayi, L. marthii, L. rocourtiae, L. weihenstephanesis, 
L. fleischmannii, L. floridensis, L. aquatica, L. cornellensis, L. riparia and L. grandensis8-10. 
Only two of this eight species are mammalian pathogens, L. monocytogenes and L. ivanovii, 
but the main specie associated with disease in humans and animals is L. monocytogenes that 
can be classified in 13 different serotypes.11 
 
1.1.1. Listeriosis  
In 2010, it was estimated about 23150 cases of human listeriosis, which led to 5463 
deaths12, but more studies on epidemiology of the disease respecting to developing countries 
are required to have more concrete information on the exact prevalence of this disease 
worldwide.  This infection is associated with the ingestion of contaminated food by L. 
monocytogenes, particularly ready-to-eat, meat, vegetables and dairy products3 where the 
major route of its contamination is the colonisation of the food - processing environment13,14.   
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In European Union the criteria for the incidence of L. monocytogenes in food is 
established through the regulation EC Nº2073/2005. The criteria imposes a limit of 100 
CFU/g in ready to eat foods (RTE) that may support the growth of L. monocytogenes during 
their shell life or is absent in 25 g at the time of delivery for distribution. 
Listeriosis occurs predominantly in two distinct levels of disease, one is a non-invasive 
gastrointestinal illness, which occurs in healthy adults where symptoms typically starts after 
18-20 hours of infection and are gastroenteritis, diarrhoea and vomiting; invasive disease, the 
more aggressive form happens in adults with underlying immunosuppression and in neonates, 
can be manifest as septicaemia or as a neuropathic disease6 (Figure 1.1.1.1). Invasive disease 
has a high mortality rate even with antibiotic treatment15.  
 
Figure 1.1.1. 1– Flow steps of human listeriosis (Lecuit, 2007)16 
 
 Vaccination against L. monocytogenes is still far away from human uses17 but due to the 
fact it is an intracellular microorganism makes it a good candidate for a live attenuated 
vaccine (LAV). In LAV the pathogen is modified to a less virulent or to an avirulent form and 
because it still viable will replicate within the host cells stimulating cell-mediated immunity. 
The main problem about this type of vaccination is the fact that the bacterium can revert to its 
original form and causes disease.18 
New approaches have been explored to fight against L. monocytogenes infection, between 
them is bacteriophage therapy that leads to lysis of the bacterium, and has FDA approval to be 
used in poultry industries during processing and packaging of raw and ready-to-eat meat19; 
essential oils that have antimicrobial properties, inhibition of listerial growth, i.e. thyme, 
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rosemary and oregano can be used in storage of vegetable 20,21; and in animal studies with 
Chinese and Japanese herbal remedies have been efficient against food poisoning by L. 
monocytogenes22.  
 Cancer research using Listeria spp. has been explored due to its possible use has a carrier 
vector of tumour-associated antigens for immunotherapy23, creation of live and attenuated 
vaccines. It was also found that ActA protein carries adjuvant properties for primary and 
metastatic tumour immunotherapy.24  
 
1.1.2. Virulence Factors  
L. monocytogenes possesses several virulence factors, the listeriolysin (LLO), a pore 
forming toxin that is encoded by hly gene one of the main factors of the bacteria 
pathogenicity25. The virulence factors LLO, the phospholipase B and C (codified by plcA and 
plcB), the metalloprotease (codified by mpl) and the internalins A and B (codified by inlA and 
inlB), which are regulated by a unique regulator, PrfA. Altogether these factors form the 
pathogenicity island of Listeria monocytogenes (LIPI-1) that has about 10 (Figure 
1.1.2.1)26,27. The PrfA regulator has a broader range of action than just the regulation of the 
virulence genes; it is known that regulates about 145 genes28.  In the infection process ActA, 
is a surface protein that forms tails that allow the passage of the pathogen into adjacent cell by 
protosion formation in the plasma membrane (Figure 1.1.2.2). L. monocytogenes possesses 
several internalins (InlA, InlB, InlC, InlJ, InlH and InlK) with different roles29: InlA interacts 
with the adhesion molecule E-cadherin in epithelial cell-cell junctions, allowing the entry into 
host cells; InlB that binds the receptor tyrosine kinase Met causing invasion of hepatocytes 
and other cell lines30; InC is expressed after the bacterium is inside the host cell and through 
some interactions slows down the innate immune system31; InlJ is an adhesion molecule 
expressed only in a later stage of infection; InlH minimizes the production of cytokine IL-6, 
in other words minimize the stimulation of the immune response32 and InlK helps the 
bacterium to escape autophagy33.  
 
 
 Figure 1.1.2. 1- Schematic organization of the pathogenicity island of Listeria 
monocytogenes (LIPI-1) (Vázquez-Boland et al., 2001)26 
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1.1.2.1. Infection mechanism of Listeria monocytogenes 
Once inside the host, L. monocytogenes invades the host cells and when within the 
phagocytic vacuoles, it manages to escape from intracellular killing by damaging the vacuolar 
membrane, by the secretion of LLO34. When in the cytoplasm, bacteria use the host sugars for 
its survival and starts to multiply and polymerize actin filament that works like a tail allowing 
its passage into an adjacent cell by formation of protrusions in the plasma membrane, evading 
T-cell recognition35(Figure 1.1.2.2). 
L. monocytogenes is able to cross the intestinal and blood-brain barrier, as well as the 
fetoplacental barrier (Figure 1.1.2.2), using InlA and InlB 2. This pathogen show strong host 
species and tissue-specific tropism, therefore the wild type is not able to infect mice16. To 
overcome the incompatibility in host-pathogen recognition L. monocytogenes was 
“murinized” by changing two amino acids in InlA to be able to bind the E-cadherin of the 
mice. The amino acid changed were Serine (Seri192InlA) to Asparagine (Asn192InlAm), this 
modification made possible the interaction by hydrogen bonds between Asn192InlAm with 
Phenylalanine (Phe17hEC1) of mice E-cadherin and changed of Tyrosine (Tyr369InlA) to Serine 
(Ser369Inlam) made possible the interaction with Asparagine (Asn27hEC1) of mice E-cadherin, 
with this modification InlAm is able to bind its mouse receptor2. 
Figure 1.1.2. 2 - Intracellular cycle of Listeria monocytogenes. 1- Entrance of L.monocytogenes 
through interactions of InlA with E-cadherin receptor and InlB with Met receptor. 2- Endocytic 
vacuole cleavage by listeriolysin-O (LLO) and phosphatidylinositide phospholipase C (Pl-PLC).                    
3- Replication of bacteria. 4- Polymerisation of cellular actin which permits intracellular mobility.   
5- Passage of bacteria into an adjacent cell. 6- Cleavage of the vacuole via secreted effectors: LLO 
and Pl-PLC. (Cossart and Lebreton, 2014)60 
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1.1.3. The Animal model for Listeriosis and Host Barriers  
To study human infection diseases, animal models have become an important tool16. The 
ideal animal model of listeriosis would allow that all phases of the disease were mimic.  
There are several limitations to achieve a good animal model, first is the fact that L. 
monocytogenes does not tolerate stomach acid which leads to require a higher dose (~108-1010 
CFU) to infect animals in comparison to the one found in humans (~106-107 CFU) 36, 37. A 
significant ability of L. monocytogenes strains to cope the gastrointestinal stress has been 
reported38, but more studies that compare differences between animals and humans gastric 
enzymes composition, stomach pH and bile content are necessary.  An additional problem 
showed in figure 1.1.3.1 is the species specificity of bacterial surface proteins InlA and InlB, 
which cause a low affinity in the interaction with the animal’s receptors decreasing the 
number of infected animals15.  
Several animals are used to study listerial infection, each one of them with specific 
limitations depending on the animal: Guinea pigs are mainly use to study maternal-foetal 
transmission of L. monocytogenes due to the fact the placenta is similar to the humans in 
opposite of other rodents, but the limitation of this animal is the fact InlB is not able to bind 
Met receptor because of an amino acid change; Gerbils have no obstacle regarding the biding 
of internalins with the respective receptors but the studies made were via middle ear infection 
which leads to an unclear understanding of the results regarding to oral infection. Thus, more 
studies are needed to establish an animal model of oral gavage; Non-human primates are the 
closest to humans but studies with this animals are very expensive and only small numbers of 
animals can be use in each study15; Mouse model in particular is very attractive because of 
genetically pure strains and similarity to humans, both physiologically and biochemically, 
nevertheless the limitation is the biding of InlA with E-cadherin receptor which was solved 
with two amino acid changes on this virulence factor 2. 
                                                                                                                                   Introduction 
6 
 
 
 
 
 
 
 
 
 
In the mouse model there are two different types of breeding, outbred and inbred. The 
most important difference between them is the fact that outbred mice have more genetic 
variability than inbred mice, which leads to a better mimic of what might happen in humans39. 
The first mouse model used for infection with L. monocytogenes was done by ingestion 
of contaminated water. Unfortunately, this method was not effective to determine the exact 
number of bacteria administered. This procedure was then replaced by directly injecting the 
inoculum into the mouse stomach (oral gavage route), which allows the operator to control 
the inoculum15. Another difficulty found was the fact L. monocytogenes is not able to survive 
the stomach acid so to overcome this problem, a suspension of calcium carbonate in PBS is 
usually use has medium to resuspend the bacteria before infection with the purpose of 
neutralize the stomach pH15. 
 This specific mouse model of oral gavage in University of Leicester was established 
using MF1 mice, however due to problems with the supplier, genetic contamination of strain, 
and change to new facilities with different air system and cleaning procedures, the model 
begin to fail. Furthermore, the supplier stop breeding MF1 mice, so the model has to be re-
established in others mouse strains, specifically CD1. 
 
Figure 1.1.3. 1 - Specificity of the internalins (InlA and InlB) according to the animal model species 
(Lecuit, 2007)16 
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Aims and Objectives 
 
The aim of this research project was the re-establishment of a mouse model of oral 
gavage by infection with Listeria monocytogenes. The mouse model consists in using the 
minimum bacterial concentration that achieves 100% of mortality. For this purpose a bacteria 
mutant was used, L. monocytogenes InlAm, which allow the bacterium to bind the mice 
receptors.  
The mouse strain MF1 was the strain used in the previous model but in virtue of genetic 
contamination a new strain was necessary to re-establish this model, and the chosen one was 
the CD1.
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1.2. Streptococcus pneumoniae 
 
 Streptococcus pneumoniae (also known as pneumococcus) was first isolated and showed 
as a pathogenic bacteria in 1880 by Sternberg and Pasteur40.  
Pneumococcus is a human pathogen that has a high rate of mortality and can cause 
invasive diseases (IPD) such as pneumonia, meningitis, septicaemia and non-invasive 
diseases such as acute otitis media (AOM)41, but most commonly it is carried in the nose of 
children without symptoms.42 According to the World Health Organization (WHO) in 2000 
there was 14.5 million cases of pneumococcal disease which lead to 826 000 deaths in infants 
below the age of 5 years old, and as can be seen in figure 1.2.1 more than 61% of this deaths 
occurred mainly in African and Asian countries 43. 
 
 
The pneumococcus is a Gram-positive, facultative anaerobic, lancet shaped coccus with a 
size between 0.5 µm to 2 µm and are usually seen as a diplococci but can also form short 
chains. Is a α-haemolytic bacterium, which means that when this activity is present the agar 
Figure 1.2. 1- Streptococcus pneumoniae global mortality rate. Deaths in children from 1 month to 5 
years per 100 000 children under the age of 5 years (O'Brien et al., 2009) 43 
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below the colony stays dark green, grow at an optimum temperature of 37º C but can survive 
in a range of temperatures from 25ºC to 40ºC 44.  
The S. pneumoniae has no less than 93 different capsular serotypes42. Serotyping is an 
important tool due to the fact that different serotypes have different virulence, potential for 
colonization and risk for invasive pneumococcal disease, and also different geographic 
regions have differing incidences of the different serotypes 45. 
 
 
1.2.1.    Pneumococcal infections 
 
Although nasopharyngeal carriage of S. pneumoniae is mainly by children of less than 5 
years, adults with acute upper respiratory infection, asthma and smoking habits also have a 
higher risk or nasopharyngeal carriage45.  
S. pneumoniae invasive disease such as pneumonia, meningitis and bacteraemia, occurs 
mainly in children under the age of 2 or in the elderly of more than 65 years. The risk of IPD 
is higher between individuals with primary or acquired immunodeficiency and in children in 
developing countries (Figure 1.2.1). In persons with immunodeficiency the incidence of IPD 
is higher when is associated with comorbidities such as alcohol abuse, congestive heart 
failure, on exposure to cigarette smoke45.  
Initially the treatment against pneumococcal infection was penicillin, but due to the 
increased number of resistant isolates specific vaccines against the most frequent serotypes 
was introduced into paediatric vaccination programs. These vaccines include conjugate 
vaccine PCV 7, 10 and 13 (covers 7, 10 and 13 serotypes) and the unconjugated vaccine 
PPV23 (covers 23 serotypes) that can be used by older children and adults with high risk of 
pneumococcal disease42,45.  
The continued use of pneumococcal vaccines led to a decrease number of infection by the 
serotypes included in the vaccine, but on the other hand infections by serotypes not included 
in the vaccines have increased, so a continued vigilance is critical to develop new vaccines 
against new serotypes45-48.   
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1.2.2. Virulence factors 
 
S. pneumoniae has a wide range of virulence factors that includes: surface proteins, 
enzymes, polysaccharide capsule and the toxin pneumolysin (Ply) 49.  
 LPXTG-anchored surface proteins, such as hyaluronidase, neuraminidase and serine 
protease PrtA have been investigated to understand their role in the virulence of the bacteria. 
It is known that hyaluronidase is involved in degradation of hyaluronic acid which can help in 
the spread and colonization by the bacteria50. Neuraminidase A is involved in colonization 
and in the progression of otitis media50. Although the specific role of PrtA is not known, it is 
known that the expression of prtA is co-regulated with others virulence factors such as the ply 
gene50.  
Lipoproteins such as pneumococcal surface adhesion protein A (PsaA) have a role in 
the adhesion to cells and are needed for full virulence. Choline-binding proteins (CBPs) such 
as pneumococcal surface protein A (PspA) do not have yet a clear function but it is known 
that is needed for full virulence50.  
One of the most important virulence factors is the polysaccharide capsule that has a 
clear role in the virulence of the bacteria as can be seen by the fact that acapsular bacteria are 
avirulent51. The capsule is known for its anti-phagocytic activity. When the capsule is present 
immunoglobulins on the bacterial cell can not interact with their receptors of the phagocytic 
cell which makes the bacteria remain extracellular50 unless an anti-capsular antibody is 
present because it has the ability to mark the pathogen allowing phagocytize. Other functions 
of the capsule is the protections against the elimination by the mucus which helps in the 
colonization step, and also minimizes the exposure of the bacterium to antibiotics50.    
The other important virulence factor is an intracellular protein sited named 
pneumolysin (Ply). It is a member of the cholesterol-dependent cytolysin (CDC) family52 and 
has two distinct activities, cytolytic (haemolytic) and the activation of the classical 
complement pathway53. The haemolytic activity occurs when the monomers of pneumolysin 
bind to the membrane surface and oligomerize. This oligomerization leads to the formation of 
rings within the cell membrane which will induce cell death54. Pneumolysin might have other 
additional unidentified function. This was observed when a mutant pneumococcus that lacks 
haemolytic and complement activity was compared with a pneumolysin negative mutant and 
still showed more virulence41. The importance of the pneumolysin was tested by construction 
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of a pneumolysin-negative mutant. The results showed that the mutant was less virulent than 
the wild-type after intranasal infection of mice52.  
 
1.2.2.1. Mechanism of infection 
 
Pneumococcal infections are transmitted from person to person via aerosols and as can 
been seen in Figure 1.2.2.1.1 the first step is the colonization of the nasopharynx, then there 
are two options, bacteria stay in the nasal cavity, asymptomatic colonization, or spread to 
other organs, such as the ears or lungs. If bacteria spread to the lungs then can cross the 
mucosal barrier, enter the blood stream and perhaps cross the blood - brain barrier and cause 
meningitis 42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.2.1. 1- Pneumococcal disease, spread by aerosol, then colonization of nasopharynx 
which can lead to asymptomatic colonization or progression to other organs causing more severe 
diseases (Normark, and Tuomanen, 2013)42 
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Aims and Objectives 
 
Streptococcus pneumoniae is a human pathogen that has a wide range of virulence factors. 
One of the virulence factors most extensively studied is the pneumolysin50. Due to this fact, 
the aim of this research was the creation of insertion mutations of the ply gene into S. 
pneumoniae D39 green fluorescent (GFP+) and S.pneumoniae D39 red fluorescent (RFP+). 
The resulting strains can be used in the future to visualise how pneumococci behaved in vivo 
in the presence or absence of pneumolysin. 
The first step consisted of the insertion of a spectinomycin resistance gene into the 
pneumolysin gene of the two fluorescent pneumococci. The next steps were the confirmation 
of mutation and also confirmation that the pneumococci had not lost fluorescence.  
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2. Materials and Methods 
 
 
2.1.  Listeria monocytogenes experiments: culture media, stocks 
and techniques 
 
The in vivo experiments involving the mice infection and their killing was performed 
by the technicians of the Central Research Facility (CRF) since is required a special license to 
perform these mice manipulation procedures.  
 
2.1.1. Culture media 
 Tryptone soya broth (TSB), Tryptone soya agar (TSA), Brain Heart Infusion Broth 
(BHI) from Oxoid, were prepared following the instructions of the manufacture 
 Calcium Carbonate Suspension (10%, w/v) was prepared in Phosphate Buffer Saline 
from Oxoid  
All culture media and solutions were sterilized by autoclaving at 122oC during 15 min at 
1.3 bar before use. 
 
2.1.2. Fresh stocks of Listeria monocytogenes InlAm  
The mutant L. monocytogenes InlAm was inoculated in TSA plates that were incubated at 
37ºC for 18-24 h. From the previous culture a loop was transferred to 10 ml of TSB. This 
bacterial suspension was incubated overnight at 37ºC with shaking (200 rpm). 
After this incubation period the optical density at 600 nm (OD600nm) was about 1.8. In case 
this was not observed the incubation has continued until this OD value was reached. 
The culture (500 µl/tube) was distributed by sterile micro tubes. The tubes were 
immediately frozen at -80ºC, and kept at this temperature until needed. After 24 h the viability 
was determined by the Miles and Misra technique55 as describe below. 
The stock tube was serially diluted by transferring 20 µl of the stock into sterile microliter 
plated containing 180 µl of sterile PBS per well. The content was homogenised by pipetting 
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up and down several times. The dilutions were prepared until 109, changing the tip after each 
dilution. 
1. The TSA plates were divided into six sectors. Each sector was inoculated with 60 µl of 
a specific dilution (104 to 109). This procedure was done in duplicate. After drying the 
spots the plates were inverted and incubated overnight at 37ºC. 
2. The colonies were counted in each sector where 100-200 colonies were visible. The 
following equation was used to calculate the number of colony forming units per ml: 
 
CFU per ml = Mean number of colonies in sector x Dilution x (100/6) 
 
2.1.3. Mice strains  
2.1.3.1. CD1 mouse strain: 
This strain is an outbred breeding and has its origin from Swiss mice, this strain can be 
used for multipurpose model, such as: general purpose, safety and efficacy (toxicology), 
oncology and aging56. 
2.1.3.2. MF1 mouse strain: 
This strain is an outbred breeding and was synthesized at OLAC (now Harlan 
Laboratories), this strain can be used for general purpose, safety and efficacy (toxicology), 
oncology and aging57. 
 
2.1.4. Preparation of infection dose for mice 
About three colonies were transferred to 40 ml of BHI. The suspension was incubated 
overnight at 37oC with shaking (200rpm). After this time interval the culture was centrifuged 
at 1400 g for 20 min, and if the OD600nm was less than 4 was discarded, but if higher it was 
continued. The culture was again centrifuged at 1400 g for 20 min and resuspend in 6 ml of 
calcium carbonate to achieve the appropriate bacterial concentration, which was 
5x109CFU/500µl. 
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2.1.5. Oral Gavage  
For this procedure 1 ml syringes and plastic feeding tubes 20 ga x 30 mm from Instech 
were used on each mouse. 
Syringe was filled with the bacterial sample, then attached to the feeding tube and 
shooked vigorously, to avoid precipitation of calcium carbonate, the mice were grabbed by 
the loose skin of the neck and back, and held vertically. The tube was inserted in the mouth of 
the mouse and the roof of the mouth was followed till reach the stomach, and then the dose 
was slowly administrated. 
 
 
2.1.6. Scoring of animal signs of Listeriosis 
The signs of Listeriosis were daily scored, as described below. 
Table 2.1.6. 1– Score of animal signs of the disease. Adapted from Morton, et al (1985)58 
Disease sign Description Numeric score 
Normal 
Active behaviour, healthy 
appearance  
1 
+ Hunched Minor curvature of the back  
2 
+ Starey coat Minor piloerection of the fur 
+ Hunched / + Starey 
Minor curvature of the back and 
piloerection of the fur 
3 
+ Hunched / ++ Starey 
Minor curvature of the back and 
distinct piloerection of the fur 
4 
++ Hunched / + Starey 
Distinct curvature of the back 
and minor piloerection of the fur  
++ Hunched / ++ Starey 
Distinct curvature of the back 
and piloerection of the fur  
5 
+ Lethargic 
Decrease of activity with distinct 
hunching and piloerection 
6 
++ Lethargic 
Severe decrease of activity with 
distinct hunching and 
piloerection  
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2.1.7. Collection of blood and tissue from infected mice 
2.1.7.1.  Blood from the tail: 
Eppendorf tubes were previously prepared with 1µl of heparin. Mice were heat in a 
thermal cage to make the veins dilate and easier to collect blood. After, the blood was treated 
as described in section 2.1.2. 
2.1.7.2.   Post-mortem tissue collection and treatment: 
When the mice achieved the lethargic stage or the end of experiment, all mice were 
anesthetized and culled by cervical dislocation. After, mice were dissected and the liver and 
spleen were collected to a universal tube with 5 ml of PBS that was previously weighted.  
The second step was the homogenization of the tissue for viable count of bacteria as 
described in section 2.1.2. 
  
                                                                                                                  Materials and Methods 
17 
 
2.2. Streptococcus pneunomiae strain D39 experiments: culture 
media, stocks and techniques  
 
2.2.1. Preparation of culture media 
 Brain Heart Infusion Broth (BHI) and Blood Agar Base (BAB) from Oxoid were 
prepared following the instructions of the manufacturer 
 Blood agar base with spectinomycin: After mixing 20 ml of horse blood, 
spectinomycin was added into 400 ml BAB with a final concentration of 100µg/ml 
 Blood agar base with chloramphenicol: After mixing 20 ml of horse blood, 
chloramphenicol was added into 400ml BAB with a final concentration of 2.5µg/ml 
 
2.2.2. Fresh stock of Streptococcus pneunomiae D39  
S. pneumoniae D39 was inoculated onto BAB plates that were incubated at 37ºC in a 
CO2 jar overnight. Then a loop of colonies was transferred to a universal tube containing 
10ml BHI. This bacterial suspension was incubate for 6 h, until the OD600nm reached 0.8. Then 
the culture was centrifuged at 2600g for 10 min and the pellet was resuspended in BHI 
containing 15% (v/v) glycerol. 
The culture was distributed into sterile Micro tubes containing 500µl in each tube. The 
tubes were immediately frozen at -80ºC until needed. After 24 h the viability was determined 
as described in section 2.1.2. 
 
2.2.3. Extraction of chromosomal DNA from S. pneunomiae D39 (Satio and 
Mariura, 1963) 
The S. pneumoniae was grown on BAB at 37ºC in a CO2 jar overnight. Next day, a 
loop of colonies were inoculated into a universal tube containing 10 ml BHI, and the 
suspension was incubated for 15 h. After this time interval, the bacterial suspension was 
centrifuged at 2000g for 10 min and pellet was resuspended in 400 µl of TE-buffer containing 
25% (w/v) of sucrose, 60 µl of 500mM EDTA, 40 µl of 10% (w/v) SDS and 2 µl Proteinase 
K were added. The suspension was transferred to an Eppendorf tube and incubated at 37ºC for 
2 h.  
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The bacterial suspension was again centrifuged at 12190g for 5 min and the upper 
aqueous phase was transferred to a fresh tube. An equal volume of chloroform:isoamyl 
alcohol (24:1) was added and the tube was centrifuged at 12190g for 10 min. After this, the 
upper aqueous phase was transferred to a fresh tube without disturbing the white protein 
layer.  
The upper aqueous phase was transferred to a fresh tube and 5 volumes of 100% 
ethanol and 0.1 volumes of 3M sodium acetate were added. The solution was centrifuged at 
9000g for 5 min. The ethanol was removed and 500 µl of 70% (v/v) ethanol was added and 
the mixture was centrifuged at 9000g for 5 min. Ethanol was removed and DNA was 
resuspend in 250 µl of TE-buffer and kept at 4oC until use. 
 
2.2.4. Amplification by polymerase chain reaction (PCR)  
 
Amplification of spectinomycin cassete, Figure 2.2.4.1, was done according the 
manufacture instructions: use of 25 µl of PrimeSTAR HS premix from Takara Biotechnology 
Inc., 2 µl of DNA template with a concentration of 20 ng/ µl, 1 µl of primer up forward of ply 
and 1 µl of primer down reverse of ply with a concentration of 1 pmol/reaction and 21 µl of 
DNA - free water from SIGMA. The parameters used in PCR were 98ºC for 10 seconds and 
30 cycles of 98ºC for 10 seconds, 55ºC for 5 seconds and 72ºC for 2.31 min. 
 
 
 
 
2.2.5. Transformation of S. pneumoniae (adapted from Bricker and Camili 
1999)  
The method used to transform this bacterium was divided in two steps, the first step is 
the competence of pneumococcus cells and the second is the transformation.  
The competent S. pneumoniae cells were given by Dr. Giuseppe from the Genetics 
Department of University of Leicester. After the competent cells were received, 2 µl of 
competence stimulating peptide (CSP) was added to 200 µl of competent cells, and the 
Spectinomycin 
Up 600  
ply arm 
Down 600 
ply arm 
Figure 2.2.4. 2 – Spectinomycin cassete that was amplified by polymerase chain reaction 
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bacterial suspension was incubated at 37ºC for 14 min. After this time interval, 5 µl of DNA 
with a concentration of 115ng/ µl was added and incubated at 37ºC for 40 min, then 100 µl of 
bacterial suspension was plated onto BAB and incubated overnight at 37ºC in a CO2 jar. 
 
2.2.6. Visualization of bacteria by confocal microscopy 
Bacteria were grown on BHI until OD600nm 0.3 was reached, 100 µl of bacterial 
suspension was placed on slides coated with gelatine. Gelatine is an adhesive compound that 
is used to. The slide was left to dry for 10min and the liquid excess was removed with a 
pipette. Then a drop of Prolong Diamond Antifade Mountant with DAPI from Probes was 
added and covered with a cover glass. Samples were ready to visualization by confocal 
microscope Olympus. 
 
2.2.7. Sonication 
 
An aliquot (500 µl) of pneumococci was left at room temperature for 5 min to thaw, after 
which the sample was centrifuged at 12190g for 5 min at 4ºC, the supernatant was removed 
and the pellet resuspended in 1ml of PBS and kept on ice. A viable count of bacteria was 
made like described in section 2.1.2.  
Sonication was done by the use of a sonication probe between 7-8 microns of amplitude. 
Sonication was for 15 seconds pulse and a 30 second pause for approximately 8 mins. The 
samples were always kept on ice and the probe cleaned with IMS between samples. A viable 
count of bacteria was made. Cells were centrifuged at 12190g for 1min, then cell debris was 
discard and then cells were ready to use. 
. 
 
2.2.8. Haemolytic Assay (in U bottom wells) 
 
Preparation of red blood cells (RBC): 10 ml of sheep blood were added to a universal tube 
and the sample was centrifuged for 5 min at 1600g. Then the serum was carefully removed 
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and 400 µl of RBC was taken from the bottom and added to a universal tube containing 10 ml 
PBS. 
Assay: 50 µl of PBS were added to each well in a total of 12 wells and 50 µl of 
pneumolysin were added to the first well and mixed by pipetting up and down several times. 
Then 50 µl were taken from the first well and added to second well, mixed and so forth. The 
tip was changed after each dilution. To finish, 50 µl of RBC were added to each well and the 
plate was incubated for 30min at 37ºC. 
The pneumolysin activity was estimated in haemolytic units per millilitre (HU/ml), which 
is given by the dilution were there was 50% of lysis. The control consisted of 50μl of PBS and 
50 μl of sheep red blood cells (4% v/v), per well. Figure 2.2.8.1 shows a plate with the toxin 
activity per 100 μl for each well. 
 
 
Figure 2.2.8. 1- Schematic representation of haemolytic assay in a round-bottom microliter plate, with 
50% lysis in the second well of row A. The number in the middle of each well indicated the toxin 
activity in HU/100 μl. Row H is the control 
 
Calculation of haemolytic activity: 
Haemolytic actitity (HU/ml) = Count until last reactive well x 10 
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Figure 3.1. 1– A) Growth curve of L. monocytogenes, optical density at 600nm measured during 
24 hours; B) number of colonies forming units per ml during 24 hours 
3. Results and Discussion of L. monocytogenes InlAm 
work 
 
3.1.  Growth curve and viability of Listeria monocytogenes InlAm  
 
 
The growth curve of L. monocytogenes was determined for the first 24 hours to 
establish the sampling times for the infection process. The growth curve is represented 
in Figure 3.1.1 the growth curve determined by the OD reads or colony count showed 
that exponential phase is completed after 8 h.  
Animal experiments are done in a period of time that can compromise the bacterial 
cell viability, and because of that it was necessary to confirm the viability of the 
inoculum during the time required (2 h). For this, bacteria were grown overnight in two 
different culture media, BHI and TSB, to see if there was an effect in the number of 
colony forming units (CFU) previously resuspend in PBS CaCO3. The viability of the 
inoculum of L. monocytogenes InlAm in PBS CaCO3 is illustrated in Figure 3.1.2. The 
recovery of viable cells did not showed any significant difference (P>0.05) between 
BHI and TSB inoculum. In virtue of this result and only because of convenience, all the 
overnight bacterial growth experiments were prepared in BHI and after re-suspension in 
CaCO3 PBS the cells were used within 2 hours. 
 
A 
B 
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Figure 3.1. 2- Viability of L. monocytogenes InlAm in PBS CaCO3 for 2 hours. Bacteria were 
grown overnight in two different media BHI and TSB. Tryptone soya broth (TSB);  Brain 
Heart Infusion broth (BHI) 
 
 
3.2. MF1 mice infected with two different doses of Listeria 
According to the literature, for animal infection the dose required is between 108-
1010CFU36, so to achieve the minimum concentration of bacteria that had 100% of 
mortality a titration of the dose was made starting in Dose A: 1x109 CFU/500 µl and 
Dose B: 3x109CFU/500 µl. After preparation of the dose 10 MF1 mice were infected by 
oral gavage. 
The mice signs of disease were inspected two times a day and scored according the 
criteria showed above in Table 2.1.6.1, until lethargic stage and then culled. The results 
of the development of the disease signs and the survival are shown in Figure 3.2.1 and 
Figure 3.2.2.  
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Theoretically it was expected that mice showed the signs of illness near 48 hours 
post infection and after 65 hours were lethargic and culled. The results of infection 
using dose A (1x109 CFU/500µl) showed 100% of survival rate, in contrast dose B 
(3x109 CFU/500µl) caused 50% survival with a median survival of 72 hours. The mice 
Figure 3.2. 1- Survival curve of MF-1 mice orally infected,  animals infected with dose A 
(1x109 CFU/500µl) of L.monocytogenes InlAm;  animals infected with dose B (3x109 
CFU/500µl) of L.monocytogenes InlAm with a median survival of 72 hours. 
Figure 3.2. 2- Signs of the disease observed in MF-1 mice after orally infected with 
L.monocytogenes InlAm,   dose A (1x109 CFU/500µl);   dose B (3x109 CFU/500µl). 
Data is representative of n = 10 animals. 
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that were not culled around 100 h post infection managed to get better and decreased the 
signs of disease, evidencing that a higher dose was required.   
Blood from the tail of each mouse were collected each day and colony forming 
units were determined. Bacteraemia appeared only 48 hours post infection and mainly 
in mice infected with the stronger dose (B) (Figure 3.2.3).  
Spleen and liver tissues were harvested after culling each animal, and viability 
was determined. The listerial colonization of spleen and liver by L. monocytogenes 
InlAm in MF1 mice is illustrated in Figure 3.2.4.  
 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
A B 
Figure 3.2. 3– Viability of L.monocytogenes InlAm collected from the blood of mice. A: 48 hours post 
infection. B: time of death. Dose A (1x109 CFU/500µl); Dose B (3x109CFU/500µl). Data is 
representative of n=10 animals. The larger bold bar represents the average value of the samples 
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A B 
Figure 3.2. 4– Recovery of L. monocytogenes InlAm from A) spleen tissue, B) liver tissue. Data is 
representative of n=10 animals. The larger bold bar represents the average value of the samples 
 
In conclusion, although there was no significant difference (P>0.05) between both 
doses, a higher dose is necessary to achieve the aim of this experiment, 100% of 
mortality. To accomplish that, a new and higher bacterial suspension was prepared to 
ensure a higher number of CFUs per 500µl. Due to the fact that the supplier was going 
to end the breeding of MF1 mice, the second experiment was done using CD1 mice and 
MF1 mice. 
 
 
 
 
 
 
 
 
                                                                                                                           Conclusion                                            
26 
 
3.3.  Infection of MF1 and CD1 mice 
A higher dose to infect MF1 and CD1 mice was prepared by resuspend bacteria in 
6ml of calcium carbonate suspension, and 5x109CFU/500µl were achieved. 
Two times a day the development of the signs of the disease were recorded and 
scored until lethargic stage and then culled. The observed, results are represented in 
Figure 3.3.1 and Figure 3.3.2. 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. 1- Survival curve of mice orally infected with L.monocytogenes InlAm: MF1 (n=10) 
with a median survival of 50 hours;  CD1 (n=17) with a median survival of 60 hours 
Figure 3.3. 2- Signs of the disease developed in MF1 (n=10) and CD1 (n=17) mice orally 
infected with L. monocytogenes InlAm. 
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 The new dose was suitable to achieve 100% mortality in CD1mice with a median 
survival of 60 hours. Regarding MF1 mice the mortality rate was 80% with a median 
survival of 50 hours. Although the aim of this experiment (100% of mortality) was not 
achieve with the MF1 mice, since this mice strain will not be used in future experiments 
(in virtue of genetic contamination) no further assays are required to establish the 
appropriate mortality dose. 
Blood from the tail of each mouse was collected once each day. Bacteraemia 
appeared at time of death in both mouse strains, and no significant differences (P>0.05) 
between mouse strains were observed. The results are represented in Figure 3.3.3. 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 3.3. 3– Viability of L.monocytogenes InlAm collected from blood. A) 48 hours post infection.  
B) at time of death. Data is representative of n=10 MF1 mice and n=17 CD1mice. The larger bold bar 
represents the average value of the samples 
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The colonization of spleen and liver tissues by L. monocytogenes InlAm was also 
evaluated.  The results are represented in Figure 3.3.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both mice strains showed the colonization of spleen and liver by 
L.monocytogenes InlAm at time of death and similar CFU were observed with no 
significant differences (P>0.05). The results are represented in Figure 3.3.4. 
The major difference between both mice strains, was the observed damage of the 
internal organs. When MF1 were culled, the internal organs had a healthy appearance, 
the colour of the liver was normal and the stomach and intestines did not showed any 
signs of the disease. In contrast the CD1 strain showed to be more injured namely, in 
the intestine some nodules were noticed, the stomach was swollen, inflated, and the 
colour of the liver was lighter than expected. 
A 
B 
Figure 3.3. 4-Recovery of L.monocytogenes InlAm from A) of spleen tissue. – B) of liver tissue. 
Data is representative of n=10 MF1 mice and n=17 CD1mice. The larger bold bar represents the 
average value of the samples 
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To validate that was the L. monocytogenes InlAm strain that caused the disease in 
mice, the inlAm gene was amplified from a colony isolated from the spleen and other 
from the liver. The expected PCR fragment is about 2.400kb. As observed in the Figure 
3.3.5, the fragment amplified correspond to the expected band in the gel. Therefore it 
was confirmed that the infection was caused by L.monocytogenes InlAm mutant.  
 
 
  
Figure 3.3. 5- Amplification of inlAm by colony PCR to confirm mutant. A) liver 
sample, B) spleen sample 
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4. Results and Discussion of S. pneumoniae work  
 
The aim of this experiment was the creation of insertion mutations of the ply gene 
into S. pneumoniae D39 green fluorescent (GFP+) and S. pneumoniae D39 red 
fluorescent (RFP+). 
 
4.1. Extraction of chromosomal DNA from pneumolysin-negative 
bacterium 
 
The first step was the extraction of the chromosomal DNA from strain S. 
pneumoniae PLNA that already was mutated in the ply gene by insertion of the 
spectinomycin resistance cassette (section 2.2.3). To confirm that the extraction was 
successfully accomplished amplification of the spectinomycin cassette by PCR was 
made (section2.2.4) and the result is presented in Figure 4.1.1. The spectinomycin 
cassette has a size of 2.358 kb and as shown in row B the size is consistent with the 
control sample, DNA extract from a bacterium that was proved to be pneumolysin-
negative and that has the spect gene, from row A.  
 
 
 
 
 
 
 
 
 
 
Figure 4.1. 1- Amplification of spectinomycin cassette by PCR using the primers of 
pneumolysin arms, the size of the cassette is 2,358 Kb. A) Positive control; B) Sample of the 
chromosomal DNA extracted 
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4.2. Transformation of S .pneumoniae GFP+ and S. pneumoniae RFP+  
 
After the extraction and amplification of the spectinomycin cassette from S. 
pneumoniae PLNA, transformation through the use of competence stimulating peptide 
of S. pneumoniae GFP+ and S. pneumoniae RFP+, with the cassette previously extracted 
(section 2.2.5), was carried out.  
To confirm the transformation, amplification by PCR was carried out using primers 
for selection of the spectinomycin gene.  The spectinomycin gene has a size of 1.158 
kb. Figure 4.2.1 summarises the findings. Row A is the wild type of S. pneumoniae 
GFP+, and row B, wild type S. pneumoniae RFP+. Both were used as a negative control. 
Row C contains S. pneumoniae PLNA. This was used as a positive control, to indicate 
where the spectinomycin gene would appear, if present. Row D represents S. 
pneumoniae GRP+/Ply-, and row E, S. pneumoniae RFP+/Ply-, the samples of both 
fluorescent bacteria. The last three rows demonstrate that the creation of insertion 
mutations of the ply gene was successfully accomplished in both bacteria. 
 
  
 
 
 
 
 
 
 
 
 Figure 4.2. 1- Amplification of spectinomycin gene (size 1,158 kb) to confirm bacterial 
transformation. Negative controls: A – S.pneumoniae D39 GFP+ (wild type), B - S.pneumoniae 
D39 RFP+ (wild type). Positive control: C - S.pneumoniae D39 PNLA ; 
Samples: D - S.pneumoniae D39 GFP+/Ply-, E - S.pneumoniae D39 RFP+/Ply- 
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4.2.1. Confirmation of bacteria fluorescence  
 
To prove that fluorescence was not lost, visualization by confocal microscopy was 
made (section 2.2.6), the analysis of Figure 4.2.1.1 A and B show that S.pneumoniae 
RFP+ after insertion mutations of the ply gene still had fluorescence and the analysis of 
Figure 4.2.1.1 C and D also show that S. pneumoniae GFP+ still have fluorescence after 
insertion mutations of the ply gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although S.pneumoniae D39 GFP+/Ply- and S.pneumoniae D39 RFP+/Ply- both 
show fluorescence but by comparing Figure 4.2.1.1B and Figure 4.2.1.1A it can be seen 
that the green bacteria have more intense fluorescence that the red. This was expected 
A B 
C D 
Figure 4.2.1. 1- Pictures of the confocal microscope, the arrows show the florescent bacteria.  
Picture A and C prove that is a bacteria showing the DNA and not debris: A) S.pneumoniae D39 
RFP+/Ply- bacterial DNA; C) S.pneumoniae D39 GFP+/Ply- bacterial DNA; Picture B and C show the 
fluorescence of the bacterium: B) S.pneumoniae D39 RFP+/Ply-; D) S.pneumoniae D39 GFP+/Ply-  
 
                                                                                                                           Conclusion                                            
33 
 
according to the previously published paper59. The explanation for this is not understood 
yet. It could be that the red fluorescent bacteria lose their fluorescence over time, or 
alternatively red fluorescent bacteria might need more time after division to express the 
fluorescence gene.  More studies are required to understand why the bacteria with the 
green protein are brighter than the bacteria with the red protein.  
 
4.2.2. Confirmation of mutation in ply gene by haemolytic assay 
  
To confirm that the toxin was removed several haemolytic assays were made 
(section 2.2.8). If the toxin (pneumolysin) was removed no haemolytic activity would 
be present and the red blood cells (RBC) would precipitate in the bottom of the plate, 
whereas if the toxin is present lysis of the RBC occurs.  
The Figure 4.2.2.1 summarizes the results of the haemolytic assays. Row A is the 
negative control where no haemolytic activity is present, row B is the wild type S. 
pneumoniae D39 (collection of laboratory 227 of University of Leicester, originally 
from the Nation Collection pf Types Cultures) and C is the wild type S. pneumoniae 
D39 (collection from Centre for Synthetic Biology, University of Groningen), where the 
presence of haemolytic activity is clear with 640 HU/ml and 320 HU/ml respectively. 
Row D is the wild type S. pneumoniae GFP+ and row E is the pneumolysin negative 
mutant of S. pneumoniae GFP+ and the difference between the haemolytic activity is 
clear with 80HU/ml and 0 HU/ml respectively. Row F is the wild type S. pneumoniae 
RFP+ and row G is the pneumolysin negative mutant of S. pneumoniae RFP+ and the 
difference between the haemolytic activity is clear with 320HU/ml and 0 HU/ml 
respectively. 
Through the results showed in Table 4.2.2. 1 and Figure 4.2.2. 1 it is legitimate to 
conclude that transformation was successfully done, the samples with pneumolysin 
removed (sample E and G) showed 0 HU/ml and the positive controls all showed 
haemolytic activity.  
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Table 4.2.2. 1- Haemolytic activity of all different S. pneumoniae D39 used in this experiment 
Sample 
Haemolytic 
activity (HU/ml) 
A- PBS 0 
B- S .pneumoniae D39 wt 
(collection of laboratory 
227 of University of 
Leicester) 
640 
C- S. pneumoniae D39 wt 
(collection from Centre for 
Synthetic Biology, 
University of Groningen) 
320 
D- S. pneumoniae D39 wt 
GFP+ 
80 
E- S .pneumoniae D39 
GFP+/Ply- 
0 
F- S. pneumoniae D39 wt 
RFP+ 
320 
G- S. pneumoniae D39 
RFP+/Ply- 
0 
  
Figure 4.2.2. 1- Haemolytic assay to confirm that the toxin pneumolysin is not presented.  
Negative control: A) PBS; Positive control: B) S. pneumoniae D39 wt (S12), C) S. pneumoniae 
D39 wt (Netherlands), D) S. pneumoniae D39 wt GFP+, F) S. pneumoniae D39 wt RFP+ ; 
Samples: E) S. pneumoniae D39 GFP+/Ply-, G) S. pneumoniae D39 RFP+/Ply- 
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5. Conclusion 
 
 The investigation of Listeria monocytogenes InlAm was successfully accomplished. 
The aim of this experiment was the re-establishment a mouse model of infection by oral 
gavage using the minimum bacterial concentration that achieves 100% of mortality. 
After some trials the minimum dose of 5x109 CFU/500µl was shown to be appropriate 
and was proved that it was sufficient to take all mice with a median survival of 60 
hours.  
 Regarding the investigation of S. pneumoniae, this was also successfully 
accomplished. The aim of this work was the creation of insertion mutations of the ply 
gene of S. pneumoniae D39/GFP+ and S. pneumoniae D39/RFP+ without loss of 
fluorescence.  
 The first step was the insertion of a spectinomycin resistance gene. Then several 
tests were made to ensure that transformation was accomplished without loss of 
fluorescence. The first test was the haemolytic assay that proved that no pneumolysin 
was in the bacteria since no haemolytic activity was presented in the mutated bacteria, 
the second test was visualization by confocal microscopy that showed that both 
fluorescent bacteria still have fluorescence after insertion mutations of the ply gene.  
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6. Future work 
 
A large collection of mutants of L. monocytogenes is available, for example 
mutations in genes required for resistance to metal, so this mouse model of oral gavage 
will be used to test the importance and roles of these genes in vivo. 
Regarding S. pneumoniae, the future work will be the visualization in vivo how 
pneumococci behave in the presence or absence of the pneumolysin toxin. For example, 
how they spread from the lungs into the blood during development of sepsis.  
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